Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $56.1 million.

  • Enanta Pharmaceuticals' Long-Term Investments changed N/A to $56.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $56.1 million, marking a year-over-year change of. This contributed to the annual value of $29.3 million for FY2022, which is 7298.83% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Long-Term Investments stood at $56.1 million for Q4 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Investments peaked at $115.7 million during Q2 2021, and registered a low of $5.9 million during Q2 2023.
  • In the last 5 years, Enanta Pharmaceuticals' Long-Term Investments had a median value of $40.8 million in 2022 and averaged $49.6 million.
  • In the last 5 years, Enanta Pharmaceuticals' Long-Term Investments crashed by 8497.48% in 2023 and then soared by 61758.95% in 2024.
  • Enanta Pharmaceuticals' Long-Term Investments (Quarter) stood at $88.7 million in 2021, then tumbled by 69.62% to $26.9 million in 2022, then plummeted by 78.01% to $5.9 million in 2023, then soared by 617.59% to $42.5 million in 2024, then soared by 31.86% to $56.1 million in 2025.
  • Its Long-Term Investments was $56.1 million in Q4 2025, compared to $42.5 million in Q2 2024 and $5.9 million in Q2 2023.